DOP2002000385A - Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3 - Google Patents

Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3

Info

Publication number
DOP2002000385A
DOP2002000385A DO2002000385A DO2002000385A DOP2002000385A DO P2002000385 A DOP2002000385 A DO P2002000385A DO 2002000385 A DO2002000385 A DO 2002000385A DO 2002000385 A DO2002000385 A DO 2002000385A DO P2002000385 A DOP2002000385 A DO P2002000385A
Authority
DO
Dominican Republic
Prior art keywords
beta
adrenorecepting
agonists
chroman derivatives
useful substitutes
Prior art date
Application number
DO2002000385A
Other languages
English (en)
Spanish (es)
Inventor
Ming Wang
Derek B Lowe
William H Bullock
Wendy Lee
Stephen J O Connor
Gaetan H Ladouceur
Ann-Marie Campbell
Miao Dai
Robert Dally
Jacques Dumas
Holia N Hatoum Mokdad
Uday Khire
Qingjie Liu
Steven R Magnuson
Ning Ql
Tatiana E Shelekhin
Quanrong Shen
Roger A Smith
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of DOP2002000385A publication Critical patent/DOP2002000385A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/04Drugs for disorders of the urinary system for urolithiasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
DO2002000385A 2001-04-23 2002-04-22 Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3 DOP2002000385A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28571901P 2001-04-23 2001-04-23
US32451801P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
DOP2002000385A true DOP2002000385A (es) 2004-01-31

Family

ID=26963345

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2002000385A DOP2002000385A (es) 2001-04-23 2002-04-22 Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3

Country Status (9)

Country Link
US (3) US6660752B2 (https=)
EP (1) EP1389202B1 (https=)
JP (1) JP2004532227A (https=)
AR (1) AR035858A1 (https=)
DE (1) DE60201437T2 (https=)
DO (1) DOP2002000385A (https=)
ES (1) ES2230487T3 (https=)
PE (1) PE20021073A1 (https=)
WO (1) WO2002085891A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
CA2566196A1 (en) * 2004-05-05 2005-11-10 F. Hoffmann-La Roche Ag Arylsulfonyl benzodioxanes useful for modulating the 5-ht6 receptor, the 5-ht2a receptor or both
BRPI0515835A (pt) * 2004-12-21 2008-08-12 Hoffmann La Roche derivados de tetralina e de indano e seus usos
ES2306275T3 (es) * 2004-12-21 2008-11-01 F. Hoffmann-La Roche Ag Derivados de cromano y sus usos como ligandos dde receptores 5-ht.
CA2591810A1 (en) 2004-12-21 2006-06-29 F.Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
SI1831159T1 (sl) * 2004-12-21 2010-04-30 Hoffmann La Roche Derivati tetralina in indana ter njune uporabe
RU2388748C2 (ru) * 2004-12-21 2010-05-10 Ф. Хоффманн-Ля Рош Аг Производные тетралина и индана и их применения в качестве антагонистов 5-нт
JP2008530229A (ja) 2005-02-17 2008-08-07 ワイス シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体
CA2628173A1 (en) * 2005-11-03 2007-05-10 F. Hoffmann-La Roche Ag Arylsulfonylchromans as 5-ht6 inhibitors indolylmaleimide derivatives as protein kinase inhibitors
GB0526252D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2418202B1 (en) 2006-03-31 2014-01-29 Novartis AG (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid derivatives as DGAT inhibitors
MX2008015511A (es) * 2006-06-20 2008-12-18 Hoffmann La Roche Derivados de arilsulfonilnaftaleno y usos de los mismos.
AU2007263075A1 (en) * 2006-06-20 2007-12-27 F. Hoffmann-La Roche Ag Arylsulfonamidyl tetralin derivatives and uses thereof
BRPI0713736A2 (pt) * 2006-06-20 2014-11-18 Hoffmann La Roche Derivados de tetralina e indano e emprego destes
SI2750677T1 (sl) * 2011-08-30 2017-10-30 Chdi Foundation, Inc. Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe
CA2895256C (en) 2013-01-09 2021-06-01 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
WO2014207648A1 (en) * 2013-06-24 2014-12-31 Lupin Limited Chromane and chromene derivatives and their use as crac modulators
CN106028817A (zh) 2013-07-08 2016-10-12 巴斯夫农业公司 包含三唑化合物和生物农药的组合物
EA037646B1 (ru) * 2013-12-12 2021-04-27 Басф Агро Б.В. Способ получения замещенных триазолов
EA201892682A1 (ru) 2014-06-25 2019-04-30 Басф Агро Б.В. Пестицидные композиции
US10053436B2 (en) 2014-07-08 2018-08-21 BASF Agro B.V. Process for the preparation of substituted oxiranes and triazoles
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
UA120628C2 (uk) 2014-11-07 2020-01-10 Басф Се Пестицидні суміші
DK3294720T3 (da) 2015-05-08 2021-02-15 Basf Agro Bv Fremgangsmåde til fremstilling af terpinolenepoxid
EP3294700B1 (en) 2015-05-08 2020-01-29 BASF Agro B.V. A process for the preparation of limonene-4-ol
US10370368B2 (en) 2015-11-30 2019-08-06 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as BLT1 antagonists
EP3383388B1 (en) 2015-11-30 2021-04-14 Merck Sharp & Dohme Corp. Aryl acylsulfonamides as blt1 antagonists
ES3056157T3 (en) 2016-03-16 2026-02-18 Basf Se Use of a specific tetrazolinone for combating resistant phytopathogenic fungi on cereals
US11241012B2 (en) 2016-03-16 2022-02-08 Basf Se Use of tetrazolinones for combating resistant phytopathogenic fungi on soybean
CA3015456C (en) 2016-03-16 2024-09-17 Basf Se USE OF TETRAZOLINONES TO CONTROL RESISTANT PLANT PATHOGENIC FUNGI ON FRUIT
US10640477B2 (en) 2016-06-15 2020-05-05 BASF Agro B.V. Process for the epoxidation of a tetrasubstituted alkene
MX2018015764A (es) 2016-06-15 2019-08-29 Basf Agro Bv Proceso para la epoxidacion de un alqueno tetrasustituido.
GB201803394D0 (en) * 2018-03-02 2018-04-18 Inflazome Ltd Novel compounds
US12545649B2 (en) 2019-11-18 2026-02-10 Vanderbilt University WDR5-MYC inhibitors
WO2024040267A2 (en) * 2022-08-19 2024-02-22 Mitokinin, Inc. Direct synthesis of n-(3-substituted-chroman-4-yl)-7h- pyrrolo[2,3-d]pyrimidin-4-amines and derivatives thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3706764A (en) 1969-04-16 1972-12-19 Yoshitomi Pharmaceutical Phenethylaminomethyl-chromanones and- thiochromanones
US3803176A (en) 1969-05-09 1974-04-09 Novo Terapeutisk Labor As Sulfonylurea derivatives
GB1499323A (en) 1974-03-22 1978-02-01 Fisons Ltd 6-substituted chromones and chromanones
DE3275295D1 (en) 1981-11-12 1987-03-05 Fisons Plc Anti-srs-a carboxylic acid derivatives, processes for their production, and pharmaceutical formulation containing them
EP0091749A3 (en) 1982-04-08 1984-12-05 Beecham Group Plc Ethanolamine derivatives, process for their preparation and pharmaceutical compositions containing them
ZA844519B (en) 1983-06-24 1985-02-27 Hoffmann La Roche Dihydrobenzopyran derivatives
US4654362A (en) 1983-12-05 1987-03-31 Janssen Pharmaceutica, N.V. Derivatives of 2,2'-iminobisethanol
DE3411992A1 (de) 1984-03-31 1985-10-10 Bayer Ag, 5090 Leverkusen Substituierte 4-hydroxy-benzopyrane, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US4727877A (en) * 1984-12-18 1988-03-01 Medtronic, Inc. Method and apparatus for low energy endocardial defibrillation
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
US5163427A (en) * 1990-11-14 1992-11-17 Medtronic, Inc. Apparatus for delivering single and multiple cardioversion and defibrillation pulses
US5117824A (en) * 1990-11-14 1992-06-02 Medtronic, Inc. Apparatus for monitoring electrical physiologic signals
US5129392A (en) * 1990-12-20 1992-07-14 Medtronic, Inc. Apparatus for automatically inducing fibrillation
FR2695387B1 (fr) 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5451677A (en) 1993-02-09 1995-09-19 Merck & Co., Inc. Substituted phenyl sulfonamides as selective β 3 agonists for the treatment of diabetes and obesity
BR9406823A (pt) 1993-06-14 1996-03-26 Pfizer Aminas secundárias e agentes anti-diabéticos e antiobesidade
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US5541197A (en) 1994-04-26 1996-07-30 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
IL113410A (en) 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
US5561142A (en) 1994-04-26 1996-10-01 Merck & Co., Inc. Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity
US5516917A (en) 1994-06-08 1996-05-14 G. D. Searle & Co. Leukotriene B4 antagonists
JPH08198866A (ja) 1995-01-20 1996-08-06 Tokyo Tanabe Co Ltd 新規2−アミノ−1−フェニルエタノール化合物
US5674254A (en) * 1995-05-22 1997-10-07 Vitatron Medical, B.V. Cardiac pacemaker system and method for determining a measure of pacing threshold without incurring loss of capture
US5663194A (en) 1995-07-25 1997-09-02 Mewshaw; Richard E. Chroman-2-ylmethylamino derivatives
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
FR2746395B1 (fr) * 1996-03-22 1998-04-17 Adir Nouveaux derives d'arylethanolamine et d'aryloxypropanolamine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3708624B2 (ja) 1996-03-27 2005-10-19 キッセイ薬品工業株式会社 3,4−ジ置換フェニルエタノールアミノテトラリンカルボン酸誘導体
EP0801060A1 (en) 1996-04-09 1997-10-15 Pfizer Inc. Heterocyclic Beta-3 Adrenergenic Agonists
WO1997046556A1 (en) 1996-06-07 1997-12-11 Merck & Co., Inc. OXADIAZOLE BENZENESULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY
ID22273A (id) 1997-01-28 1999-09-23 Merck & Co Inc TIAZOL BENZENASULFONAMIDA SEBAGAI AGONIS β UNTUK PENGOBATAN DIABETES DAN OBESITAS
US5741312A (en) * 1997-03-12 1998-04-21 Vitatron Medical, B.V. Pacemaker system and method with improved capture detection and threshold search
JP2001526282A (ja) * 1997-12-19 2001-12-18 バイエル・コーポレーシヨン β−3アドレナリン受容体作用薬として有用なカルボキシル置換クロマン誘導体
US6051586A (en) 1997-12-19 2000-04-18 Bayer Corporation Sulfonamide substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6469031B1 (en) * 1998-12-18 2002-10-22 Bayer Corporation Carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists
US6052621A (en) * 1998-01-27 2000-04-18 Vitatron Medical B.V. System and method for inducing tachycardia
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US6393316B1 (en) * 1999-05-12 2002-05-21 Medtronic, Inc. Method and apparatus for detection and treatment of cardiac arrhythmias
US6647292B1 (en) * 2000-09-18 2003-11-11 Cameron Health Unitary subcutaneous only implantable cardioverter-defibrillator and optional pacer
US6675042B2 (en) * 2002-04-15 2004-01-06 Charles D. Swerdlow Defibrillation shock strength determination technology

Also Published As

Publication number Publication date
US6660752B2 (en) 2003-12-09
US6919371B2 (en) 2005-07-19
EP1389202A1 (en) 2004-02-18
EP1389202B1 (en) 2004-09-29
DE60201437T2 (de) 2005-12-15
DE60201437D1 (de) 2004-11-04
US20050215594A1 (en) 2005-09-29
US20030078260A1 (en) 2003-04-24
US20040072828A1 (en) 2004-04-15
ES2230487T3 (es) 2005-05-01
JP2004532227A (ja) 2004-10-21
WO2002085891A1 (en) 2002-10-31
PE20021073A1 (es) 2002-12-12
AR035858A1 (es) 2004-07-21

Similar Documents

Publication Publication Date Title
DOP2002000385A (es) Derivados de cromano 2,6-sustituidos utiles como agonistas adrenoreceptores beta-3
UY27065A1 (es) Agonistas de beta-3 adreno-receptores de derivados de aminometil cromano di-sustituido
BR0116026A (pt) Imidazoquinolinas substituìdas por tioéter
HN2003000416A (es) Derivados de pirrolopirimidina
ES2151277T3 (es) Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
ECSP055524A (es) Derivados de indolin-fenilsufonamida
CR8410A (es) Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
BR0308639A (pt) Composições, artigo, método para repelir qualquer um ou mais membros do grupo de insetos, processo para a produção de di-hidronepetalactona
HN2000000051A (es) Derivados heterociclicos utiles como agentes anticancerosos
BR0211905A (pt) Dialdeìdos de rapamicina
BR0113184A (pt) Implante artificial e processo para produzir o mesmo
CR9149A (es) Derivados de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos
ECSP074704A (es) Combinaciones de inhibidor(es) de la absorción de esterol con modificador(es) sanguíneos para tratar cuadros vasculares
BRPI0413180A (pt) gorduras de baixo teor de ácido trans-groxo e composições de gorduras, e métodos de fazer as mesmas
ATE500747T1 (de) Zusammensetzung zur erhöhung der leistungsfähigkeit des körpers
AR032499A1 (es) Composiciones
PA8437901A1 (es) Procedimientos e intermedios para preparar derivados de cromanol sustituidos
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos
BR9814302A (pt) Derivados de cromano de carboxila substituìda úteis como agonistas do adrenorreceptor beta 3
BR0212246A (pt) Composição indutora da resistência a doença de planta, método para controlar uma doença de planta, e, processo para a produção de uma composição
PL1626974T3 (pl) Podstawione benzopirany jako selektywne związki agonistyczne receptora beta estrogenu
UY27268A1 (es) Derivados de cromano 2, 6-sustituidos útiles como agonistas adrenorrecptores beta-3
GT200600326A (es) Diazepinoquinolinas, sintesis de las mismas e intermediarios de las mismas
SV2003001002A (es) Derivados de cromano 2,6-sustituidos utiles como agonistas adrenorreceptores beta-3 ref.5062-sv
BR0214694A (pt) 1,3-diarilprop-2-en-1-onas, composições que as contêm e utilização